Immunomodulatory strategies for ex vivo immune cell expansion in adoptive cell therapy: translational and regulatory considerations for clinical manufacturing
- 1Bioengineering and Automation, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR)
- 2Department of Food Science and Technology, National University of Singapore
Abstract
Ex vivo expansion is a fundamental yet challenging step in the manufacturing of adoptive cell therapies (ACT), as therapeutic success relies on generating enough functional immune cells while maintaining their phenotype, metabolic fitness, and persistence. This review provides a comprehensive overview of immunomodulatory strategies designed to enhance cell yield during ex vivo expansion, categorizing them into cell-intrinsic and cell-extrinsic approaches. Cell-intrinsic strategies, including gene editing and gene transfer technologies, enable precise modulation of survival pathways, proliferation, metabolic state, and resistance to exhaustion. These tools support the production of more potent and durable immune cell products. In contrast, cell-extrinsic strategies shape immune cell behavior through cytokine supplementation, checkpoint blockade, nutrient and metabolic modulation, feeder cell systems, synthetic activation platforms, and biophysical cues such as oxygen tension and bioreactor-controlled environments. Together, these strategies provide coordinated signals that direct activation, differentiation, and persistence during expansion in culture. The review also highlights key regulatory considerations, including distinctions between genetically and non-genetically modified products, risk assessments associated with human and animal-derived materials, ancillary material qualification, and process scalability for clinical translation. By integrating biological, engineering, and regulatory perspectives, this paper outlines principles for scalable immunomodulation platforms designed with regulatory considerations in mind to advance next-generation ACT manufacturing.
Related
- Toward Long-Acting Injectable Antidepressants: Drug-Delivery Strategies, Clinical Considerations, and Regulatory Barriers.
- Polydeoxyribonucleotide (PDRN) in Osteoarthritis: Immunomodulatory and Matrix-Supportive Potential, A2A Receptor-Associated Mechanisms, and Translational Challenges
- Celastrol in Rheumatoid Arthritis: Immunomodulatory Mechanisms, Multicellular Convergence, and Translational Challenges
- Immunomodulatory potential of Mongolian medicine in sepsis: current evidence, challenges, and translational perspectives
- WHO Target Product Profiles for Dengue Therapeutics: An Interdisciplinary Analysis of Ethical, Regulatory, and Implementation Considerations
BibTeX
@article{chan2026immunomodulatory,
title = {{Immunomodulatory strategies for ex vivo immune cell expansion in adoptive cell therapy: translational and regulatory considerations for clinical manufacturing}},
author = {Weng Wan Chan and Estella Zhi Yu Lim and Deepak Choudhury},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1861621},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1861621/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immunomodulatory strategies for ex vivo immune cell expansion in adoptive cell therapy: translational and regulatory considerations for clinical manufacturing
AU - Weng Wan Chan
AU - Estella Zhi Yu Lim
AU - Deepak Choudhury
PY - 2026
DA - 2026/10/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1861621
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1861621/full
AB - Ex vivo expansion is a fundamental yet challenging step in the manufacturing of adoptive cell therapies (ACT), as therapeutic success relies on generating enough functional immune cells while maintaining their phenotype, metabolic fitness, and persistence. This review provides a comprehensive overview of immunomodulatory strategies designed to enhance cell yield during ex vivo expansion, categorizing them into cell-intrinsic and cell-extrinsic approaches. Cell-intrinsic strategies, including gene editing and gene transfer technologies, enable precise modulation of survival pathways, proliferation, metabolic state, and resistance to exhaustion. These tools support the production of more potent and durable immune cell products. In contrast, cell-extrinsic strategies shape immune cell behavior through cytokine supplementation, checkpoint blockade, nutrient and metabolic modulation, feeder cell systems, synthetic activation platforms, and biophysical cues such as oxygen tension and bioreactor-controlled environments. Together, these strategies provide coordinated signals that direct activation, differentiation, and persistence during expansion in culture. The review also highlights key regulatory considerations, including distinctions between genetically and non-genetically modified products, risk assessments associated with human and animal-derived materials, ancillary material qualification, and process scalability for clinical translation. By integrating biological, engineering, and regulatory perspectives, this paper outlines principles for scalable immunomodulation platforms designed with regulatory considerations in mind to advance next-generation ACT manufacturing.
SN - 1664-3224
ER -